Clinical management of pulmonary sarcoidosis

References

• Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173.
   PubMed Web of Science ®Google Scholar
• Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19–27.
   PubMed Web of Science ®Google Scholar
• Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J. 1961;4:1165–1172.
   Google Scholar
• Nagai S, Shigematsu M, Hamada K, et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med. 1999;5(5):293–298.
   PubMedGoogle Scholar
• Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2009;136:526–535.
   PubMed Web of Science ®Google Scholar
• Oberstein A, Von Zitzewitz H, Schweden F, et al. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14(1):65–72.
   PubMed Web of Science ®Google Scholar
• Patil SN, Levin DL. Distribution of thoracic lymphadenopathy in sarcoidosis using computed tomography. J Thorac Imaging. 1999;14(2):114–117.
   PubMed Web of Science ®Google Scholar
• Polverosi R, Russo R, Coran A, et al. Typical and atypical pattern of pulmonary sarcoidosis at high-resolution CT: relation to clinical evolution and therapeutic procedures. Radiol Med. 2014;119(6):384–392.
   PubMed Web of Science ®Google Scholar
• Trisolini R, Anevlavis S, Tinelli C, et al. CT pattern of lymphadenopathy in untreated patients undergoing bronchoscopy for suspected sarcoidosis. Respir Med. 2013;107(6):897–903.
   PubMed Web of Science ®Google Scholar
• Ors F, Gumus S, Aydogan M, et al. HRCT findings of pulmonary sarcoidosis; relation to pulmonary function tests. Multidiscip Respir Med. 2013;8(1):8.
   PubMed Web of Science ®Google Scholar
• Drent M, de Vries J, Lenters M, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol. 2003;13(11):2462–2471.
   PubMed Web of Science ®Google Scholar
• Hansell DM, Milne DG, Wilsher ML, et al. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology. 1998;209(3):697–704.
   PubMed Web of Science ®Google Scholar
• Muller NL, Mawson JB, Mathieson JR, et al. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology. 1989;171(3):613–618.
   PubMed Web of Science ®Google Scholar
• Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol. 2000;174(6):1751–1757.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med. 2013;107:2009–2013.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014;2(2):123–130.
   PubMed Web of Science ®Google Scholar
• Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1996;35:1647–1649.
   Web of Science ®Google Scholar
• Vorselaars AD, Crommelin HA, Deneer VH, et al. Effectiveness of infliximab in refractory FDG PET positive sarcoidosis. Eur Respir J. 2015;46:175–185.
   PubMed Web of Science ®Google Scholar
• Cremers JP, Van Kroonenburgh MJ, Mostard RL, et al. Extent of disease activity assessed by 18F-FDG PET/CT in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):37–45.
   PubMed Web of Science ®Google Scholar
• Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949–1953.
   PubMed Web of Science ®Google Scholar
• Mostard RL, Voo S, Van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105(12):1917–1924.
   PubMed Web of Science ®Google Scholar
• Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53(10):1543–1549.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36(7):1131–1137.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011;55(1):66–71.
   PubMed Web of Science ®Google Scholar
• Mostard RL, Verschakelen JA, Van Kroonenburgh MJ, et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med. 2012;105(2):1917–1924.
   PubMed Web of Science ®Google Scholar
• Rubini G, Cappabianca S, Altini C, et al. Current clinical use of 18FDG-PET/CT in patients with thoracic and systemic sarcoidosis. Radiol Med. 2014;119(1):64–74.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–1889.
   PubMed Web of Science ®Google Scholar
• Lofgren S, Lundback H. The bilateral hilar lymphoma syndrome: a study of the relation to age and sex in 212 cases. Acta Med Scand. 1952;142:259–264.
   PubMedGoogle Scholar
• Grunewald J, Eklund A. Sex-specific manifestations of Lofgren’s syndrome. Am J Respir Crit Care Med. 2007;175(1):40–44.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128(3):1483–1489.
   PubMed Web of Science ®Google Scholar
• Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):147–153.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007;132(1):207–213.
   PubMed Web of Science ®Google Scholar
• Rothkrantz-Kos S, Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49(9):1510–1517.
   PubMed Web of Science ®Google Scholar
• Lieberman J. Elevation of serum angiotensin converting enzyme (ACE) level in sarcoidosis. Am J Med. 1975;59:365–372.
   PubMed Web of Science ®Google Scholar
• DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme in evaluating the clinical courseof sarcoidosis. Ann Intern Med. 1980;92:361–365.
   PubMed Web of Science ®Google Scholar
• Gronhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis. 1980;61(2):113–122.
   PubMedGoogle Scholar
• Baughman RP, Ploysongsang Y, Roberts RD, et al. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis. 1983;128:631–633.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573–581.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Verwoerd A, Van Moorsel CH, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–609.
   PubMed Web of Science ®Google Scholar
• Fleischer M, Hinz A, Brahler E, et al. Factors associated with fatigue in sarcoidosis. Respir Care. 2014;59(7):1086–1094.
   PubMed Web of Science ®Google Scholar
• de Kleijn WP, de Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med. 2009;15(5):499–506.
   PubMed Web of Science ®Google Scholar
• Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, et al. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med. 2008;102(11):1636–1642.
   PubMed Web of Science ®Google Scholar
• Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997–1004.
   PubMed Web of Science ®Google Scholar
• De BS, Wilsher ML. Validation of the sarcoidosis health questionnaire in a non-US population. Respirology. 2012;17(3):519–524.
   PubMed Web of Science ®Google Scholar
• Judson MA, Mack M, Beaumont JL, et al. Validation and important differences for the sarcoidosis assessment tool. A new patient-reported outcome measure. Am J Respir Crit Care Med. 2015;191(7):786–795.
   PubMed Web of Science ®Google Scholar
• Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King’s sarcoidosis questionnaire for the assessment of health status. Thorax. 2013;68(1):57–65.
   PubMed Web of Science ®Google Scholar
• Judson MA, Chaudhry H, Louis A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015;109(4):526–531.
   PubMed Web of Science ®Google Scholar
• de Vries J, Michielsen H, Van Heck GL, et al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004;9(Pt 3):279–291.
   PubMed Web of Science ®Google Scholar
• Lower EE, Malhotra A, Surdulescu V, et al. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage. 2013;45(2):159–169.
   PubMed Web of Science ®Google Scholar
• Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008;133(5):1189–1195.
   PubMed Web of Science ®Google Scholar
• Drent M, Mulder PG, Wagenaar SS, et al. Differences in BAL fluid variables in interstitial lung diseases evaluated by discriminant analysis. Eur Respir J. 1993;6(6):803–810.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M. Role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med. 2001;22(2):331–341.
   PubMed Web of Science ®Google Scholar
• Welker L, Jörres RA, Costabel U, et al. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J. 2004;24(6):1000–1006.
   PubMed Web of Science ®Google Scholar
• Kantrow SP, Meyer KC, Kidd P, et al. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J. 1997;10(12):2716–2721.
   PubMed Web of Science ®Google Scholar
• Drent M, Jacobs JA, Cobben NA, et al. Computer program supporting the diagnostic accuracy of cellular BALF analysis: a new release. Respir Med. 2001;95(10):781–786.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Dohn MN, Loudon RG, et al. Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. Chest. 1991;99(1):92–97.
   PubMed Web of Science ®Google Scholar
• Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–1014.
   PubMed Web of Science ®Google Scholar
• Tremblay A, Stather DR, Maceachern P, et al. A randomized controlled trial of standard vs endobronchial ultrasonography-guided transbronchial needle aspiration in patients with suspected sarcoidosis. Chest. 2009;136(2):340–346.
   PubMed Web of Science ®Google Scholar
• Gupta D, Dadhwal DS, Agarwal R, et al. Endobronchial ultrasound-guided transbronchial needle aspiration vs conventional transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest. 2014;146(3):547–556.
   PubMed Web of Science ®Google Scholar
• Trisolini R, Lazzari AL, Tinelli C, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for diagnosis of sarcoidosis in clinically unselected study populations. Respirology. 2015;20(2):226–234.
   PubMed Web of Science ®Google Scholar
• Von Bartheld MB, Dekkers OM, Szlubowski A, et al. Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial. Jama. 2013;309(23):2457–2464.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Srinivasan A, Aggarwal AN, et al. Efficacy and safety of convex probe EBUS-TBNA in sarcoidosis: a systematic review and meta-analysis. Respir Med. 2012;106(6):883–892.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of conventional transbronchial needle aspiration in sarcoidosis: a systematic review and meta-analysis. Respir Care. 2013;58(4):683–693.
   PubMed Web of Science ®Google Scholar
• Trisolini R, Lazzari AL, Cancellieri A, et al. Transbronchial needle aspiration improves the diagnostic yield of bronchoscopy in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(2):147–151.
   PubMed Web of Science ®Google Scholar
• Navani N, Booth HL, Kocjan G, et al. Combination of endobronchial ultrasound-guided transbronchial needle aspiration with standard bronchoscopic techniques for the diagnosis of stage I and stage II pulmonary sarcoidosis. Respirology. 2011;16(3):467–472.
   PubMed Web of Science ®Google Scholar
• Puri R, Mangla R, Eloubeidi M, et al. Diagnostic yield of EUS-guided FNA and cytology in suspected tubercular intra-abdominal lymphadenopathy. Gastrointest Endosc. 2012;75(5):1005–1010.
   PubMed Web of Science ®Google Scholar
• Hunsaker AR, Munden RF, Pugatch RD, et al. Sarcoidlike reaction in patients with malignancy. Radiology. 1996;200(1):255–261.
   PubMed Web of Science ®Google Scholar
• Cancellieri A, Leslie KO, Tinelli C, et al. Sarcoidal granulomas in cytological specimens from intrathoracic adenopathy: morphologic characteristics and radiographic correlations. Respiration. 2013;85(3):244–251.
   PubMed Web of Science ®Google Scholar
• Dhooria S, Agarwal R, Aggarwal AN, et al. Differentiating tuberculosis from sarcoidosis by sonographic characteristics of lymph nodes on endobronchial ultrasonography: a study of 165 patients. J Thorac Cardiovasc Surg. 2014;148(2):662–667.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001;120(1):109–114.
   PubMed Web of Science ®Google Scholar
• Goyal A, Gupta D, Agarwal R, et al. Value of different bronchoscopic sampling techniques in diagnosis of sarcoidosis: a prospective study of 151 patients. J Bronchology Interv Pulmonol. 2014;21(3):220–226.
   PubMedGoogle Scholar
• Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS ONE. 2014;9(2):e86716.
   PubMed Web of Science ®Google Scholar
• Karfis EA, Roustanis E, Beis J, et al. Video-assisted cervical mediastinoscopy: our seven-year experience. Interact Cardiovasc Thorac Surg. 2008;7:1015–1018.
   PubMedGoogle Scholar
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–127.
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717–723.
   PubMed Web of Science ®Google Scholar
• Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet. 2014;383(9923):1155–1167.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol. 2012;8(1):95–103.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J. 2013;41:1424–1438.
   PubMed Web of Science ®Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Qjm. 2006;99(5):307–315.
   PubMed Web of Science ®Google Scholar
• Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis. 1998;15:52–58.
   Google Scholar
• Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine. 1999;78:65–111.
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest. 1999;116:424–431.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):198–204.
   PubMed Web of Science ®Google Scholar
• Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19:545–561.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60–66.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846–851.
   PubMedGoogle Scholar
• Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci. 1990;299:153–157.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54:742–746.
   PubMed Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med. 1994;121:833–841.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:87–92.
   PubMed Web of Science ®Google Scholar
• Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117–1122.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate versus azathioprine in second line therapy of sarcoidosis. Chest. 2013;144:805–812.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38:1145–1150.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43–48.
   PubMed Web of Science ®Google Scholar
• Cannon GW, Holden WL, Juhaeri J, et al. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol. 2004;31(10):1906–1911.
   PubMed Web of Science ®Google Scholar
• Hamzeh N, Voelker A, Forssen A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108:1663–1669.
   PubMed Web of Science ®Google Scholar
• Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86:376–383.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015;10:813–822.
   Web of Science ®Google Scholar
• Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):56–64.
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Crommelin HA, Vorselaars AD, Van Moorsel CH, et al. Anti-TNF therapeutics for the treatment of sarcoidosis. Immunotherapy. 2014;6(10):1127–1143.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:201–208.
   PubMed Web of Science ®Google Scholar
• Orum M, Hilberg O, Krag S, et al. Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J. 2012;59(12):A4535.
   PubMed Web of Science ®Google Scholar
• Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522–528.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Loftus EV Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99(10):1984–1989.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Ingledue R, et al. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:26–33.
   PubMed Web of Science ®Google Scholar
• Wong AK, Kerkoutian S, Said J, et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol. 2012;31(4):631–636.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014;108(1):189–194.
   PubMed Web of Science ®Google Scholar
• Sones M, Israel HL, Dratman MB, et al. Effect of cortisone in sarcoidosis. N Engl J Med. 1951;244(6):209–213.
   PubMed Web of Science ®Google Scholar
• Miller MA, Bass HE. Effect of Acthar-c (ACTH) in sarcoidosis. Ann Intern Med. 1952;37(4):776–784.
   PubMed Web of Science ®Google Scholar
• Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol. 2012;8(2):122–128.
   Web of Science ®Google Scholar
• Brod SA, Morales MM. Bio-equivalence of IM and SQ H.P. Acthar Gel. Biomed Pharmacother. 2009;63(4):251–253.
   PubMed Web of Science ®Google Scholar
• Arnason BG, Berkovich R, Catania A, et al. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler. 2013;19(2):130–136.
   PubMed Web of Science ®Google Scholar
• Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29(8):1570–1577.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Barney JB, O’hare L, et al. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016;110:66–72.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol. 2012;6:1613–1618.
   PubMedGoogle Scholar
• Krause ML, Cooper LT, Chareonthaitawee P, et al. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2015;55:189–191.
   PubMed Web of Science ®Google Scholar
• Beccastrini E, Vannozzi L, Bacherini D, et al. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm. 2013;21(3):244–246.
   PubMed Web of Science ®Google Scholar
• Cinetto F, Compagno N, Scarpa R, et al. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19–0025.
   PubMedGoogle Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528.
   PubMed Web of Science ®Google Scholar
• Lanini S, Molloy AC, Fine PE, et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36.
   PubMed Web of Science ®Google Scholar
• Daikeler T, Kistler AD, Martin PY, et al. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). Swiss Med Wkly. 2015;145:w14103. doi:10.4414/smw.2015.14103.eCollection;%2015.:w14103.
   Google Scholar
• Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529–535.
   PubMed Web of Science ®Google Scholar
• Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis. 2012;71(8):1303–1308.
   PubMed Web of Science ®Google Scholar
• Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006;129(1):174–181.
   PubMed Web of Science ®Google Scholar
• Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38(3):628–634.
   PubMed Web of Science ®Google Scholar
• de Kleijn WP, de Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med. 2009;15(5):499–506.
   PubMed Web of Science ®Google Scholar
• Hoitsma E, De VJ, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med. 2011;105(1):95–100.
   PubMed Web of Science ®Google Scholar
• Elfferich MD, Nelemans PJ, Ponds RW, et al. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration. 2010;80:212–219.
   PubMed Web of Science ®Google Scholar
• Hoitsma E, Faber CG, Van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(1):73–77.
   PubMed Web of Science ®Google Scholar
• Parambil JG, Tavee JO, Zhou L, et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med. 2011;105(1):101–105.
   PubMed Web of Science ®Google Scholar
• Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double blind, pilot study. Mol Med. 2012;18:1430–1436.
   PubMed Web of Science ®Google Scholar
• Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung. 2011;189(2):167–172.
   PubMed Web of Science ®Google Scholar
• Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2013;41(3):621–626.
   PubMed Web of Science ®Google Scholar
• Jamilloux I, Valeyre D, Lortholary O, et al. The spectrum of opportunistic diseases complicating sarcoidosis. Autoimmun Rev. 2015;14(1):64–74.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Fungal infections as a complication of therapy for sarcoidosis. Qjm. 2005;98:451–456.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138:1078–1085.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis associated pulmonary hypertension: A double-blind placebo controlled randomized trial. Chest. 2014;145:810–817.
   PubMed Web of Science ®Google Scholar
• Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience. Chest. 2009;135:1455–1461.
   PubMed Web of Science ®Google Scholar
• Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005;60(1):32–38.
   PubMed Web of Science ®Google Scholar
• Kabitz HJ, Lang F, Walterspacher S, et al. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006;130(5):1496–1502.
   PubMed Web of Science ®Google Scholar
• Karadalli MN, Bosnak-Guclu M, Camcioglu B, et al. Effects of inspiratory muscle training in subjects with sarcoidosis: a randomized controlled clinical trial. Respir Care. 2015 Dec 29. pii:respcare.04312. [Epub ahead of print].
   PubMedGoogle Scholar
• Strookappe B, Swigris J, De VJ, et al. Benefits of physical training in sarcoidosis. Lung. 2015;193(5):701–708.
   PubMed Web of Science ®Google Scholar
• Marcellis R, Van der Veek M, Mesters I, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(1):53–62.
   PubMed Web of Science ®Google Scholar
• Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med. 2010;31(4):409–418.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:90–98.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528.
   PubMed Web of Science ®Google Scholar
• Sharma OP, Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest. 1988;94(2):343–346.
   PubMed Web of Science ®Google Scholar
• Handa T, Nagai S, Fushimi Y, et al. Clinical and radiographic indices associated with airflow limitation in patients with sarcoidosis. Chest. 2006;130(6):1851–1856.
   PubMed Web of Science ®Google Scholar
• Chambellan A, Turbie P, Nunes H, et al. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest. 2005;127(2):472–481.
   PubMed Web of Science ®Google Scholar
• Van den Heuvel DA, de Jong PA, Zanen P, et al. Chest computed tomography-based scoring of thoracic sarcoidosis: inter-rater reliability of CT abnormalities. Eur Radiol. 2015;25(9):2558–2566.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J. 2013;41(3):743–751.
   PubMed Web of Science ®Google Scholar